CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-11 | Adsett Roger Director | Grant or award · Stock Option (Right to Buy) | +14,620 | 14,620 | ||
| 2026-06-11 | Bruhn Suzanne Louise Director | Grant or award | +4,666 | 24,289 | ||
| 2026-06-11 | Bruhn Suzanne Louise Director | Grant or award · Stock Option (Right to Buy) | +19,188 | 19,188 | ||
| 2026-03-25 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 | −8,018 | $18.47 | $148K | 413,317 |
| 2026-03-25 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −10,702 | $18.47 | $198K | 271,079 |
| 2026-03-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −24,431 | $18.47 | $451K | 752,454 |
| 2026-02-03 | Wiley Matthew T. Chief Commercial Officer | Grant or award | +115,000 | 115,000 | ||
| 2026-02-03 | Roberts Brandi Chief Financial Officer | Grant or award | +150,000 | 150,000 | ||
| 2026-02-03 | Sullivan Mark Chief Legal Officer | Grant or award | +125,000 | 407,576 | ||
| 2026-02-03 | Karlin Daniel Chief Medical Officer | Grant or award | +150,000 | 575,025 | ||
| 2026-02-03 | Barrow Robert Chief Executive Officer | Grant or award | +320,000 | 1,098,477 | ||
| 2026-01-29 | Adsett Roger Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2025-12-26 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 | −5,600 | $13.15 | $74K | 425,025 |
| 2025-12-26 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −25,791 | $13.15 | $339K | 778,477 |
| 2025-12-26 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −11,276 | $13.15 | $148K | 282,576 |
| 2025-09-25 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −11,278 | $9.77 | $110K | 293,852 |
| 2025-09-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −25,797 | $9.77 | $252K | 804,268 |
| 2025-09-25 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 | −7,704 | $9.77 | $75K | 430,625 |
| 2025-06-25 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −11,491 | $6.80 | $78K | 305,130 |
| 2025-06-25 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 | −7,848 | $6.80 | $53K | 438,329 |
Page 3 of 12 · 225 trades